Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Uricosuric agent

Probenecid

Dosage form
Tablet
Available strengths
500 mg
Drug class
Uricosuric agent
Common brand
Generic products

Clinical overview. Probenecid is a uricosuric agent that lowers serum urate by blocking its renal tubular reabsorption, used as an alternative or add-on urate-lowering therapy for chronic gout and hyperuricemia when a xanthine oxidase inhibitor is contraindicated, not tolerated, or insufficient alone.

Indication

Common therapeutic uses

  • Alternative urate-lowering therapy for chronic gout and hyperuricemia in patients who cannot use, do not tolerate, or have an inadequate response to a xanthine oxidase inhibitor (allopurinol or febuxostat).
  • Adjunctive use with certain antibiotics (for example, penicillins) to raise and prolong their serum concentration by blocking renal tubular secretion, when this effect is specifically desired.
  • Not indicated for treatment of an acute gout flare and not indicated for asymptomatic hyperuricemia.

Pregnancy

Risk assessment and monitoring considerations

  • Human reproductive data are limited; use only if the potential benefit justifies the potential risk to the fetus, and only when a xanthine oxidase inhibitor is not a suitable alternative.

Breastfeeding

Infant exposure considerations

  • Data on excretion into breast milk are limited; use the lowest effective dose if treatment cannot be deferred and monitor the infant, or consider an alternative agent with more established lactation data.

Geriatrics

Dosing and tolerability considerations

  • No specific dose adjustment beyond standard renal-function-based dosing; assess renal function before starting and periodically during therapy, since both efficacy and hypersensitivity risk are influenced by renal clearance.

Pediatrics

Use in children and adolescents

  • Not established for gout in children. Pediatric gout is rare and, when it occurs, warrants specialist evaluation for an underlying inherited enzyme disorder rather than routine uricosuric therapy. Contraindicated under 2 years of age.

Dosage & Administration

Practical dosing and administration

  • Starting dose: 250 mg PO twice daily for the first week, then 500 mg PO twice daily; alternatively, initiate directly at 500 mg PO once or twice daily.
  • Titration: may increase by 500 mg every 4 weeks if the serum urate target is not reached and the drug is tolerated, up to a maximum of 2 g/day in divided doses.
  • Do not start until any acute gout flare has fully resolved. If a flare occurs after probenecid has already been established as maintenance therapy, continue probenecid unchanged and treat the flare separately with colchicine, an NSAID, or a corticosteroid.
  • Take with food or milk to reduce gastrointestinal upset, and maintain a high fluid intake (at least 2 to 3 L/day) throughout treatment to reduce the risk of urate kidney stone formation, particularly in the first months of therapy.
  • Confirm creatinine clearance before starting. Do not use as first-line monotherapy if ClCr is under 50 mL/min or if there is a history of urolithiasis.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose may cause central nervous system stimulation, including seizures, following initial sedation. Manage supportively with attention to airway, breathing, and circulation, and institute seizure precautions. There is no specific antidote.

Common side effects

Frequently reported tolerability concerns

  • Nausea, anorexia, and gastrointestinal upset, more common at higher doses.
  • Headache.
  • Flushing.
  • Urinary frequency.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Hypersensitivity reactions, including rash, pruritus, fever, and rare anaphylaxis.
  • Urate nephrolithiasis, particularly early in therapy or with inadequate fluid intake.
  • Rare hepatic necrosis, nephrotic syndrome, aplastic anemia, or hemolytic anemia (the last especially in glucose-6-phosphate dehydrogenase [G6PD] deficiency).

Use with caution

Situations requiring closer assessment

  • History of peptic ulcer disease.
  • Renal impairment - reduced efficacy and increased urate nephrolithiasis risk as renal function declines.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Contraindications

Situations where therapy may be inappropriate

  • Known hypersensitivity to probenecid.
  • Blood dyscrasias.
  • Known uric acid overproduction (substantially elevated 24-hour urinary uric acid) - uricosurics are contraindicated in gross uric acid overproducers.
  • History of urate nephrolithiasis.
  • Children under 2 years of age.
  • Concurrent initiation during an untreated acute gout flare.

Drug interactions

Clinically relevant combinations

  • Reduces renal tubular secretion of many drugs, increasing and prolonging their serum levels - includes penicillins, cephalosporins, and methotrexate; dose adjustment of the interacting drug may be required.
  • Salicylates, including low-dose acetylsalicylic acid, antagonize the uricosuric effect and should not be used for pain relief during probenecid therapy - continue low-dose ASA for cardiovascular protection if it is already indicated, but choose a non-salicylate analgesic for other pain.
  • May increase levels of sulfonylureas and some benzodiazepines.
  • Urine alkalinizing agents are not recommended in patients taking a uricosuric.

Food interactions

Meal-related administration

  • Take with food or milk to reduce gastrointestinal upset; no specific food avoidance is otherwise required.

Time of administration

Practical scheduling

  • Twice daily, with food; space doses evenly through the day.

Storage

Product handling

  • Store at room temperature, protected from moisture, out of the reach of children.

Patient take-away

Key counselling points for a quick closing summary

  • Probenecid helps your body remove more uric acid through your kidneys, lowering the uric acid level in your blood over time to prevent future gout attacks. It does not relieve pain during an attack that is already happening.
  • Drink plenty of fluids (at least 2 to 3 litres a day, unless your prescriber has told you to limit fluids for another reason) throughout treatment to reduce the risk of kidney stones.
  • Avoid aspirin and other salicylate-containing products while taking this medicine unless your prescriber has specifically told you to continue low-dose aspirin for heart protection - salicylates block the effect of probenecid.
  • Keep taking this medicine every day, even when you feel well - stopping it can allow uric acid levels to rise again and increase your risk of future gout attacks.
  • Tell your prescriber right away about a new rash, fever, unusual bruising or bleeding, or reduced urination.

References

Source material and product information

  1. DailyMed Probenecid Tablets, USP - Official FDA Product Label

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.